New BPA for valchlor
Active Awarded Last action
- Contract number
- 36E79725A0008
- Awardee
-
Helsinn Therapeutics (U.s.), Inc. UEI H7RDUVXHP8L3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 80% complete
- IDV ceiling
- $8,338,904.40
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Helsinn Therapeutics (U.S.), Inc. has been awarded a single Blanket Purchase Agreement (BPA) by the National Acquisition Center to supply VALCHLOR, a 0.01265% topical gel formulation indicated for the treatment of cutaneous T-cell lymphoma. This civilian procurement vehicle, established under the Pharmaceuticals and Drugs (FSS-61-IB) General Services Administration Schedule, carries a ceiling value of $8,338,904.40 and represents an exercise of option year one under existing BPA 36E79725A0008. The contract operates without small business set-asides and extends through March 11, 2027, following the award date of March 12, 2025. As a specialized oncologic pharmaceutical product, VALCHLOR will be distributed through Department of Veterans Affairs medical facilities on an as-needed basis to support veteran patient care requirements.
The BPA structure enables efficient procurement mechanisms whereby Veterans Integrated Service Networks and individual VA medical facilities may place orders against the established ceiling without requiring separate competitive procurement actions for each transaction. This indefinite delivery vehicle arrangement reflects the Department of Veterans Affairs' recurring demand for VALCHLOR in support of cutaneous T-cell lymphoma treatment protocols across the veteran healthcare system. Helsinn Therapeutics' established federal contract portfolio, which includes multiple BPAs and a complementary Federal Supply Schedule contract with a $33.6 million ceiling through February 2030, demonstrates the contractor's sustained capability to meet federal pharmaceutical supply requirements. The contract performance will be executed as a prime contract within the United States by the registered vendor operating under Unique Entity Identifier H7RDUVXHP8L3.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0008?
36E79725A0008 was awarded to Helsinn Therapeutics (U.s.), Inc. by National Acquisition Center (Headquarters) on March 12, 2025.
How much is contract 36E79725A0008 worth?
36E79725A0008's own ceiling is $8,338,904.
Who can order from contract 36E79725A0008?
36E79725A0008 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0008 under another contract?
Yes. 36E79725A0008 is a blanket purchase agreement under 36F79725D0061, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0008 competed?
The extent of competition for 36E79725A0008 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV